XTL Biopharma Balance Sheet - Annual (NASDAQ:XTLB)

Add to My Stocks
$1.78 $0.02 (1.14%) XTLB stock closing price Sep 20, 2018 (Closing)

A thorough fundamental analysis involves using data from XTL Biopharma balance sheet, apart from other financial statements, to value the business. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our XTL Biopharma stock analysis. A company releases its balance sheet every year along with its annual results. Apart from analyzing XTL Biopharma revenue XTL Biopharma operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The XTL Biopharma balance sheet for 2017 shows cash on hand of $3.28M. The company has a debt to equity ratio of 0.

View latest 10 year balance sheet data to check XTL Biopharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Marketable Securities----1.27M1.61M1.37M---
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets2.5M---------
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances-----2.33M----
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable----------
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses---------1.05M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities2.66M---------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net13.18M6.62M6.6M6.19M6.09M5.99M5.33M4.99M1.44M1.44M
Capital Surplus146.01M150.78M150.74M148.27M148.32M147.47M141.38M139.98M139.78M149.08M
Retained Earnings-155.64M-154.9M-152.48M-148.32M-146.07M-143.56M-143.27M-142.14M-141.22M-149.1M
Treasury Stock----2.09M2.46M----
Other Liabilities----1.47M-1.98M----
Shareholders Equity3.61M2.68M4.88M4.67M6.78M9.42M3.44M2.83M-1.42M
Total Liabilities & Shareholders Equity6.58M3.01M5.32M5.64M8.01M11.08M4.07M3.79M-3.43M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The latest XTL Biopharma stock price, and XTL Biopharma historical stock prices show the stock price movement over time, and the XTL Biopharma PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: An asset is a resource that a corporation like XTL Biopharma owns and has monetary significance. XTLB assets grew from $3.01M in 2016 to $6.58M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: The total liabilities of XTL Biopharma for the year 2017 total to $2.96M. Liabilities for a company like XTL Biopharma include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

XTL Biopharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover